SF 1221

as introduced - 90th Legislature (2017 - 2018) Posted on 02/21/2017 09:05am

A bill for an act
relating to human services; allowing the early periodic screening, diagnosis, and
treatment program to cover stiripentol; amending Minnesota Statutes 2016, section
256B.0625, subdivision 64.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:

Section 1.

Minnesota Statutes 2016, section 256B.0625, subdivision 64, is amended to
read:

Subd. 64.

Investigational drugs, biological products, and devices.

Medical assistance
and the early periodic screening, diagnosis, and treatment (EPSDT) program do not cover
costs incidental to, associated with, or resulting from the use of investigational drugs,
biological products, or devices as defined in section 151.375 new text begin , except that stiripentol may
be covered by the EPSDT program for an eligible enrollee with a documented diagnosis of
Dravet syndrome, for whom all other available covered prescription medications for Dravet
syndrome have been exhausted. Stiripentol may only be covered if the United States Food
and Drug Administration has approved the treating physician's individual patient
investigational new drug application (IND) for the use of stiripentol for treatment or
emergency use new text end .